{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:26:12Z","timestamp":1787819172773,"version":"build-2784847793"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Guangdong Province Science and Technology Major Plan Project","award":["2014B020212019"],"award-info":[{"award-number":["2014B020212019"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Prophylactic peripheral photocoagulation has been proposed to be applied to persistent, peripheral, avascular retina for retinopathy of prematurity (ROP) patients who have received an intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) agents. However, there are doubts regarding the necessity of this prophylactic action regardless of fundus fluorescein angiography (FFA) results. The adverse prognosis for persistent avascular retina after anti-VEGF therapy in ROP patients is not well understood. The relationship between vascular leakage and an adverse prognosis is also unknown. Therefore, it would be of value to study the above issues to shape the treatment strategy of persistent avascular retina after intravitreal anti-VEGF therapy in ROP patients.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods\/design<\/jats:title>\n<jats:p>This is a prospective study of ROP patients with persistent avascular retina who have received anti-VEGF intravitreal therapy and have never received laser therapy. All the eyes being studied will be followed up and examined by FFA after anti-VEGF treatment and categorized into two groups, a leakage group and a non-leakage group according to the extent of vascular leakage from FFA results. The eyes being studied in the leakage group will be further randomized into two groups, a laser group and a non-laser group. A cohort study (observational) will be conducted on the non-leakage group and the non-laser group (with leakage) to investigate the incidence of an adverse prognosis for reactivation, retinal tear and retinal detachment; as well as to investigate the relationship between vascular leakage from FFA results and the abovementioned pathological changes. A randomized controlled study (experimental) will be conducted on the leakage group to compare the prognosis between the laser group and the non-laser group.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Discussion<\/jats:title>\n<jats:p>The present study aims to investigate the occurrence rates of an adverse prognosis including reactivation, retinal tear and retinal detachment after anti-VEGF therapy in ROP patients with persistent avascular retina; to assess the relationship between vascular leakage from FFA results and the abovementioned pathological changes; to compare the prognosis of persistent avascular retina with or without prophylactic peripheral photocoagulation in these patients; to shape the treatment strategy and provide evidence for the indications of prophylactic photocoagulation.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>Chinese Clinical Trial Registry (ChiCTR), ID: ChiCTR-ROC-17013253. Registered on 5 November 2017. <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/showproj.aspx?proj=22703\">http:\/\/www.chictr.org.cn\/showproj.aspx?proj=22703<\/jats:ext-link><\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13063-020-04371-6","type":"journal-article","created":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T09:05:57Z","timestamp":1591607157000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Study protocol for prognosis and treatment strategy of peripheral persistent avascular retina after intravitreal anti-VEGF therapy in retinopathy of prematurity"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5284-2734","authenticated-orcid":false,"given":"Ying","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wensi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoman","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,8]]},"reference":[{"issue":"2","key":"4371_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.earlhumdev.2007.11.009","volume":"84","author":"C Gilbert","year":"2008","unstructured":"Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev. 2008;84(2):77\u201382.","journal-title":"Early Hum Dev"},{"issue":"2","key":"4371_CR2","doi-asserted-by":"publisher","first-page":"F179","DOI":"10.1136\/archdischild-2014-306207","volume":"100","author":"A Fielder","year":"2015","unstructured":"Fielder A, Blencowe H, O\u2019Connor A, Gilbert C. Impact of retinopathy of prematurity on ocular structures and visual functions. Arch Dis Child Fetal Neonatal Ed. 2015;100(2):F179\u201384.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"3","key":"4371_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.survophthal.2016.12.004","volume":"62","author":"ME Hartnett","year":"2017","unstructured":"Hartnett ME. Advances in understanding and management of retinopathy of prematurity. Surv Ophthalmol. 2017;62(3):257\u201376.","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"4371_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jaapos.2017.10.006","volume":"22","author":"KA Kennedy","year":"2018","unstructured":"Kennedy KA, Mintz-Hittner HA, Group B-RC. Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity. J AAPOS. 2018;22(1):61\u20135.e1.","journal-title":"J AAPOS"},{"issue":"7","key":"4371_CR5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ, Group B-RC. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603\u201315.","journal-title":"N Engl J Med"},{"issue":"2","key":"4371_CR6","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ophtha.2017.08.005","volume":"125","author":"D Lepore","year":"2018","unstructured":"Lepore D, Quinn GE, Molle F, Orazi L, Baldascino A, Ji MH, et al. Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings. Ophthalmology. 2018;125(2):218\u201326.","journal-title":"Ophthalmology"},{"issue":"3","key":"4371_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jaapos.2013.01.004","volume":"17","author":"S Ittiara","year":"2013","unstructured":"Ittiara S, Blair MP, Shapiro MJ, Lichtenstein SJ. Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab. J AAPOS. 2013;17(3):323\u20135.","journal-title":"J AAPOS"},{"issue":"6","key":"4371_CR8","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/archophthalmol.2011.1802","volume":"130","author":"RD Patel","year":"2012","unstructured":"Patel RD, Blair MP, Shapiro MJ, Lichtenstein SJ. Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity. Arch Ophthalmol. 2012;130(6):801\u20132.","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"4371_CR9","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","volume":"130","author":"J Hu","year":"2012","unstructured":"Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol. 2012;130(8):1000\u20136.","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"4371_CR10","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3928\/23258160-20160229-12","volume":"47","author":"LL Snyder","year":"2016","unstructured":"Snyder LL, Garcia-Gonzalez JM, Shapiro MJ, Blair MP. Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging Retina. 2016;47(3):280\u20133.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"2","key":"4371_CR11","first-page":"124","volume":"78","author":"AL Bashinsky","year":"2017","unstructured":"Bashinsky AL. Retinopathy of prematurity. N C Med J. 2017;78(2):124\u20138.","journal-title":"N C Med J"},{"issue":"4","key":"4371_CR12","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1097\/IAE.0000000000001581","volume":"38","author":"JM Garcia Gonzalez","year":"2018","unstructured":"Garcia Gonzalez JM, Snyder L, Blair M, Rohr A, Shapiro M, Greenwald M. Prophylactic peripheral laser and fluorescein angiography after bevacizumab for retinopathy of prematurity. Retina. 2018;38(4):764\u201372.","journal-title":"Retina"},{"issue":"11","key":"4371_CR13","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","volume":"121","author":"D Lepore","year":"2014","unstructured":"Lepore D, Quinn GE, Molle F, Baldascino A, Orazi L, Sammartino M, et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology. 2014;121(11):2212\u20139.","journal-title":"Ophthalmology"},{"issue":"2","key":"4371_CR14","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jaapos.2013.12.009","volume":"18","author":"A Henaine-Berra","year":"2014","unstructured":"Henaine-Berra A, Garcia-Aguirre G, Quiroz-Mercado H, Martinez-Castellanos MA. Retinal fluorescein angiographic changes following intravitreal anti-VEGF therapy. J AAPOS. 2014;18(2):120\u20133.","journal-title":"J AAPOS"},{"issue":"4","key":"4371_CR15","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","volume":"98","author":"SG Tahija","year":"2014","unstructured":"Tahija SG, Hersetyati R, Lam GC, Kusaka S, McMenamin PG. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity. Br J Ophthalmol. 2014;98(4):507\u201312.","journal-title":"Br J Ophthalmol"},{"issue":"Suppl 3","key":"4371_CR16","first-page":"53","volume":"25","author":"V Purcaro","year":"2012","unstructured":"Purcaro V, Baldascino A, Papacci P, Giannantonio C, Molisso A, Molle F, et al. Fluorescein angiography and retinal vascular development in premature infants. J Matern Fetal Neonatal Med. 2012;25(Suppl 3):53\u20136.","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"1","key":"4371_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12938-018-0556-7","volume":"17","author":"Z Jiang","year":"2018","unstructured":"Jiang Z, Yu Z, Feng S, Huang Z, Peng Y, Guo J, et al. A super-resolution method-based pipeline for fundus fluorescein angiography imaging. Biomed Eng Online. 2018;17(1):125.","journal-title":"Biomed Eng Online"},{"key":"4371_CR18","volume-title":"Sample size calculations in clinical research","author":"S-C Chow","year":"2008","unstructured":"Chow S-C, Shao J, Wang H. Sample size calculations in clinical research. 2nd ed. Boca Raton: Chapman & Hall\/CRC; 2008.","edition":"2"},{"issue":"9","key":"4371_CR19","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","volume":"123","author":"HA Mintz-Hittner","year":"2016","unstructured":"Mintz-Hittner HA, Geloneck MM, Chuang AZ. Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy. Ophthalmology. 2016;123(9):1845\u201355.","journal-title":"Ophthalmology"},{"key":"4371_CR20","doi-asserted-by":"publisher","unstructured":"Cryotherapy for Retinopathy of Prematurity Cooperative Group and the National Eye Institute, Bethesda, Md. Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol. 1988;106(4):471\u20139. https:\/\/doi.org\/10.1001\/archopht.1988.01060130517027.","DOI":"10.1001\/archopht.1988.01060130517027"},{"issue":"7","key":"4371_CR21","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archopht.123.7.991","volume":"123","author":"International Committee for the Classification of Retinopathy of Prematurity","year":"2005","unstructured":"International Committee for the Classification of Retinopathy of Prematurity. The International classification of retinopathy of prematurity revisited. Arch Ophthalmol. 2005;123(7):991\u20139.","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"4371_CR22","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/S0031-3955(16)36370-2","volume":"34","author":"JT Flynn","year":"1987","unstructured":"Flynn JT. Retinopathy of prematurity. Pediatr Clin N Am. 1987;34(6):1487\u2013516.","journal-title":"Pediatr Clin N Am"},{"issue":"2","key":"4371_CR23","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0161-6420(93)31665-9","volume":"100","author":"DB Schaffer","year":"1993","unstructured":"Schaffer DB, Palmer EA, Plotsky DF, Metz HS, Flynn JT, Tung B, et al. Prognostic factors in the natural course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology. 1993;100(2):230\u20137.","journal-title":"Ophthalmology"},{"issue":"9","key":"4371_CR24","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/S0161-6420(01)00660-1","volume":"108","author":"RS Kaiser","year":"2001","unstructured":"Kaiser RS, Trese MT, Williams GA, Cox MS Jr. Adult retinopathy of prematurity: outcomes of rhegmatogenous retinal detachments and retinal tears. Ophthalmology. 2001;108(9):1647\u201353.","journal-title":"Ophthalmology"},{"issue":"4","key":"4371_CR25","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.ajo.2007.11.007","volume":"145","author":"RS Kaiser","year":"2008","unstructured":"Kaiser RS, Fenton GL, Tasman W, Trese MT. Adult retinopathy of prematurity: retinal complications from cataract surgery. Am J Ophthalmol. 2008;145(4):729\u201335.","journal-title":"Am J Ophthalmol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-04371-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-020-04371-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-04371-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T23:37:55Z","timestamp":1623109075000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-020-04371-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,8]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4371"],"URL":"https:\/\/doi.org\/10.1186\/s13063-020-04371-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,8]]},"assertion":[{"value":"26 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study is approved by the Research Ethics Committee of Guangzhou Women and Children\u2019s Medical Center, Guangzhou Medical University, Guangzhou, China; Registry number: 2017102609; Registry date: 2 November 2017. This study is also approved by the Chinese Clinical Trial Registry (ChiCTR); Registry number: ChiCTR-ROC-17013253; Registry date: 5 November 2017. Title: Prospective cohort study on the pathogenesis and prognosis of retinopathy of prematurity. The manuscript was written adhering to Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines\/methodology. Any important protocol modifications will be communicated to the investigators, trial participants and trial registries.The study procedures will be explained to the patients\u2019 parents orally with a witness present if they are illiterate, or in writing if literate. A patient will be recruited into the study only after the consent form has been obtained by the clinicians and signed by the patient\u2019s parents.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Personal information of the enrolled patients will be used confidentially before, during and after the study. The results of the study will be published in scientific journals and presented at conferences. To convey the results to the trial participants, the results will also be published on the official platform of our hospital using the Wechat app (China).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"493"}}